Global Bromfenac Sodium (CAS 91714-93-1) Market Size By Type (Original Drug, Generic Drug), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Bromfenac Sodium (CAS 91714-93-1) Market was valued at USD 625 million in 2023 and is projected to reach USD 1.04 billion by 2031, growing at a CAGR of 6.7% during the forecast period from 2023 to 2031. Bromfenac Sodium, a potent non-steroidal anti-inflammatory drug (NSAID), is widely used in ophthalmic formulations to manage postoperative inflammation and pain in patients undergoing cataract surgery. The rising geriatric population, increasing prevalence of eye-related disorders, and advancements in ophthalmic drug delivery systems are the primary factors fueling market growth.

Drivers:

1. Rising Geriatric Population and Eye Disorder Prevalence

Aging populations are more susceptible to eye conditions such as cataracts, leading to increased surgical procedures and higher demand for postoperative treatment options like Bromfenac Sodium.

2. Advancements in Drug Formulations

Improved formulations, such as once-daily dosing and enhanced drug bioavailability, have boosted patient compliance and clinical outcomes, contributing to market expansion.

3. Increasing Cataract Surgeries and Reimbursement Support

The global increase in cataract surgeries and supportive reimbursement policies in developed markets are creating favorable conditions for the uptake of ophthalmic NSAIDs like Bromfenac Sodium.

Restraints:

1. Side Effects and Regulatory Challenges

Despite its effectiveness, Bromfenac Sodium may cause side effects like burning sensation, eye irritation, or delayed wound healing, leading to caution in long-term or high-frequency use. Additionally, stringent regulatory approval processes can delay new product launches.

2. Market Competition from Alternative Therapies

The availability of other NSAIDs and corticosteroid eye drops, often at lower costs, may limit Bromfenac’s market share in price-sensitive regions.

Opportunity:

1. Expanding Access in Emerging Markets

Developing regions, especially in Asia-Pacific and Latin America, are witnessing increased access to ophthalmic care, driven by healthcare reforms and growing awareness, offering new growth avenues for market players.

2. Product Innovation and Combination Therapies

Innovation in ophthalmic drug delivery technologies (e.g., sustained-release formulations) and the development of combination products that incorporate Bromfenac Sodium with antibiotics or lubricants provide untapped commercial potential.

Market by System Type Insights:

The Ophthalmic Solution segment dominated the market in 2023, owing to its established clinical use and ease of administration. However, the Ophthalmic Suspension segment is expected to gain traction due to improved stability and targeted drug delivery advantages, especially in treating chronic inflammatory eye conditions.

Market by End-use Insights:

Hospitals remained the largest end-user segment in 2023, accounting for over 45% of the global revenue. This is primarily due to the high volume of cataract surgeries conducted in hospital settings. Meanwhile, Ophthalmic Clinics are anticipated to experience the fastest growth due to increasing outpatient surgical procedures and the growing number of specialized eye care centers.

Market by Regional Insights:

North America led the global Bromfenac Sodium market in 2023, supported by a high prevalence of age-related eye disorders, strong healthcare infrastructure, and favorable reimbursement scenarios. Asia-Pacific is forecast to grow at the highest CAGR during the period, propelled by an expanding elderly population base, increasing surgical interventions, and government initiatives for vision care in countries like India, China, and Japan.

Competitive Scenario:

Key players operating in the Global Bromfenac Sodium Market include Bausch + Lomb, Santen Pharmaceutical Co., Ltd., Sun Pharma, Ajanta Pharma, Apotex Inc., and Amneal Pharmaceuticals. These companies are actively focusing on regulatory approvals, portfolio expansion, and collaborations to strengthen their foothold.

Key Developments Include:

2023: Bausch + Lomb launched an advanced preservative-free formulation of Bromfenac eye drops in North America.

2024: Ajanta Pharma received regulatory approval for its generic version of Bromfenac Sodium in several African countries.

2025: Santen Pharmaceutical initiated a partnership with an AI health-tech firm to develop predictive models for post-surgical inflammation treatment efficacy.

Scope of Work – Global Bromfenac Sodium (CAS 91714-93-1) Market

Report Metric Details

Market Size (2023) USD 625 million

Projected Market Size (2031) USD 1.04 billion

CAGR (2023–2031) 6.7%

Market Segments By System Type (Solution, Suspension), End-use (Hospitals, Clinics), Region

Growth Drivers Rising eye disorder prevalence, innovations in ophthalmic formulations, aging global population

Opportunities Expansion in emerging markets, new drug delivery technologies, combination therapies

Key Market Developments:

Bausch + Lomb (2023): Introduced preservative-free Bromfenac for sensitive eyes.

Ajanta Pharma (2024): Gained WHO prequalification for Bromfenac Sodium distribution.

Amneal Pharmaceuticals (2025): Launched a high-stability ophthalmic suspension variant across U.S. clinics.

FAQs:

1) What is the current market size of the Global Bromfenac Sodium (CAS 91714-93-1) Market?

The market was valued at USD 625 million in 2023.

2) What is the major growth driver of the Global Bromfenac Sodium Market?

The key driver is the increasing number of cataract surgeries and rising geriatric population globally.

3) Which is the largest region during the forecast period in the Bromfenac Sodium Market?

North America is the largest region, driven by advanced healthcare systems and high surgical volumes.

4) Which segment accounted for the largest market share in the Bromfenac Sodium Market?

The Ophthalmic Solution segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Bromfenac Sodium Market?

Key players include Bausch + Lomb, Santen Pharmaceutical, Sun Pharma, Ajanta Pharma, and Apotex Inc.

Let me know if you'd like the same format for another topic!